MS Frontiers 2022

The nationwide Transforming MS for All project 5:19
The nationwide Transforming MS for All project
Joela Mathews • 22 Jul 2022
Addressing the MS care paradox in the UK 3:39
Addressing the MS care paradox in the UK
Joela Mathews • 22 Jul 2022
What is the role of a neuropharmacist? 6:24
What is the role of a neuropharmacist?
Joela Mathews • 22 Jul 2022
How are MS services coping across the UK? 5:20
How are MS services coping across the UK?
Joela Mathews • 22 Jul 2022
Diet quality and clinical progression in MS over 7.5 years of follow-up 7:00
Diet quality and clinical progression in MS over 7.5 years of follow-up
Steve Simpson-Yap • 29 Jun 2022
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation 6:02
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation
Klaus Schmierer • 1 Jul 2022
Targeting paramagnetic rim lesions in multiple sclerosis 2:10
Targeting paramagnetic rim lesions in multiple sclerosis
Alberto Calvi • 6 Jul 2022
The relationship between slowly expanding lesions and paramagnetic rim lesions in multiple sclerosis 6:47
The relationship between slowly expanding lesions and paramagnetic rim lesions in multiple sclerosis
Alberto Calvi • 6 Jul 2022
Increasing incidence and prevalence of MS in Tasmania, Australia 5:11
Increasing incidence and prevalence of MS in Tasmania, Australia
Steve Simpson-Yap • 29 Jun 2022
Developing biomarkers for individual prognostication in MS 3:34
Developing biomarkers for individual prognostication in MS
Klaus Schmierer • 1 Jul 2022
Early diagnosis and treatment for multiple sclerosis prevention 2:44
Early diagnosis and treatment for multiple sclerosis prevention
Klaus Schmierer • 1 Jul 2022
Slowly expanding lesions as predictive biomarkers in MS 6:14
Slowly expanding lesions as predictive biomarkers in MS
Alberto Calvi • 6 Jul 2022
What underlies the increased prevalence and incidence of multiple sclerosis in Tasmania? 2:25
What underlies the increased prevalence and incidence of multiple sclerosis in Tasmania?
Steve Simpson-Yap • 29 Jun 2022
ChariotMS: the first DMT trial in advanced multiple sclerosis 3:19
ChariotMS: the first DMT trial in advanced multiple sclerosis
Klaus Schmierer • 1 Jul 2022
The developing role of vitamin D and sun exposure in multiple sclerosis onset and clinical course 2:40
The developing role of vitamin D and sun exposure in multiple sclerosis onset and clinical course
Steve Simpson-Yap • 29 Jun 2022
The content of VJNeurology is intended for healthcare professionals